Andreas Engert
MD
Professor of Internal Medicine, Hematology and Oncology
👥Biography 个人简介
Andreas Engert leads the German Hodgkin Study Group and has shaped modern PET-adapted treatment strategies for Hodgkin lymphoma. He led studies demonstrating that PET-guided escalation and de-escalation can optimize outcomes while minimizing late toxicity. His work on replacing bleomycin with brentuximab vedotin in frontline regimens (BrECADD) has established a new potential standard that reduces pulmonary toxicity. He has also studied consolidation radiation de-escalation in early-stage favorable disease.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-03-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Andreas Engert 的研究动态
Follow Andreas Engert's research updates
留下邮箱，当我们发布与 Andreas Engert（University of Cologne / German Hodgkin Study Group）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment